Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T13:41:21.297Z.
Calculation as of: 2026-10-06T13:41:21.297Z.
Quote observation: 2026-10-06T13:40:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fe921af54d6420969180622b7fbdd7ef934f73e64ffcc47ddb287d73eacb5931
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$11.21M
PS Ratio
N/A
TTM Avg
3.04
3Y Avg
3.04
5Y Avg
6193.39
Market Cap
$10.86M
PS Ratio
N/A
TTM Avg
32.91
3Y Avg
62.07
5Y Avg
66.46
Market Cap
$11.39M
PS Ratio
113.88
TTM Avg
104.86
3Y Avg
73.15
5Y Avg
73.15
Market Cap
$10.38M
PS Ratio
34.75
TTM Avg
104.45
3Y Avg
295.11
5Y Avg
603.14
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioVie Inc. (BIVI) | $11.09M | N/A | N/A | N/A | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.21M | N/A | 3.04 | 3.04 | 6193.39 |
| Biofrontera Inc. (BFRI)vs › | $11.27M | 0.24 | 0.28 | 0.18 | 0.48 |
| Cerenome, Inc. (CNSY)vs › | $11.29M | 2.69 | 4.41 | 4.41 | 4.41 |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.86M | N/A | 32.91 | 62.07 | 66.46 |
| Lisata Therapeutics, Inc. (LSTA)vs › | $11.39M | 113.88 | 104.86 | 73.15 | 73.15 |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $10.38M | 34.75 | 104.45 | 295.11 | 603.14 |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.65M | N/A | N/A | N/A | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.07M | 0.32 | 0.98 | 1.40 | 2.22 |
| Caring Brands, Inc. (CABR)vs › | $10.55M | 9091.51 | 9868.69 | 9868.69 | 9868.69 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q1 FY2026Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-10 |
| Q2 FY2026Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-06 |
| Q3 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-11 |
| Q4 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
